Opportunity Information: Apply for RFA CA 22 008
This opportunity, RFA-CA-22-008, is a National Institutes of Health (NIH) National Cancer Institute (NCI) funding announcement that supports revision applications to existing, currently funded NCI P01 Program Project Grants. In practical terms, it is not meant for brand-new P01 proposals. Instead, it is designed for research teams that already hold an active NCI P01 and want to make a substantial, well-justified change to the funded project by adding a specific new capability: a novel technical approach or instrument that was developed with support from NCI's Innovative Molecular Analysis Technologies (IMAT) program. The overall idea is to speed up cancer research progress by inserting a proven, NCI-backed emerging technology into an ongoing, well-structured program project where it can immediately be tested, validated, and used to answer important cancer research questions.
The core purpose of the revisions is to expand the parent P01's original research questions or to accelerate the pace and impact of the parent study. Applicants are expected to show that the proposed technology integration is not just an incremental upgrade, but a meaningful addition that can change what the parent project can measure, analyze, or discover. The FOA places strong emphasis on independent validation, meaning the work supported through the revision should help demonstrate that the IMAT-developed tool or method is reliable, useful, and ready for broader adoption by the appropriate cancer research community. In other words, this is partly a bridge between technology development and real-world research use: it encourages investigators to take an emerging IMAT technology and prove its value in a rigorous cancer research setting, rather than leaving it as a promising prototype.
Because the FOA is positioned as a component of the IMAT program, it also reflects IMAT's broader goals: pushing interdisciplinary collaboration and creating innovative tools and methods that enable cancer research and accelerate scientific discovery. Applicants should expect that reviewers will be looking for a clear rationale for why the chosen IMAT-supported technology is a good match for the scientific aims of the parent P01, how it will be implemented, what validation steps will be used, and how the revision will tangibly increase the impact, speed, or scope of the original program project. The title indicates "Clinical Trial Optional," which signals that the revision may include clinical trial-related components if appropriate, but clinical trials are not required for responsiveness.
From an administrative standpoint, this is a discretionary grant opportunity under NIH, categorized under Education and Health, with CFDA number 93.394. The funding instrument type is a grant, and the announcement explicitly focuses on revision applications (formerly referred to as competing revisions). The award ceiling listed in the source data is $150,000, indicating a relatively targeted add-on budget intended to support the added technology integration and associated validation work rather than a major expansion in overall project scale. The original closing date shown is 2022-09-22, and the creation date is 2022-01-03, which helps situate the opportunity in time.
Eligibility is broad in terms of institution types, consistent with many NIH opportunities, but the key eligibility constraint is programmatic: the applicant must be revising an active NCI P01 award. Eligible applicant organizations listed include public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, and various levels of government entities (state, county, city/township, special district), as well as tribal governments and tribal organizations. The announcement also highlights additional eligible groups, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and even non-domestic (non-U.S.) entities (foreign organizations). This broad list underscores that, as long as the applicant organization can legitimately hold the award and is tied to an eligible, currently funded NCI P01, a wide range of institutional settings can participate.
In summary, this FOA is best understood as a targeted NCI mechanism to rapidly move IMAT-supported technologies into active, high-impact cancer research programs by funding competitive revisions to existing NCI P01 projects. It aims to accelerate discovery by pairing emerging, NCI-funded technology innovations with established research teams and infrastructures, while simultaneously generating independent validation evidence that can help those tools become credible, adoptable resources for the broader cancer research community.Apply for RFA CA 22 008
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
- This funding opportunity was created on 2022-01-03.
- Applicants must submit their applications by 2022-09-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $150,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is RFA-CA-22-008?
RFA-CA-22-008 is a National Institutes of Health (NIH) National Cancer Institute (NCI) funding announcement that supports revision applications (formerly called competing revisions) to existing, currently funded NCI P01 Program Project Grants.
Is this opportunity for brand-new P01 applications?
No. This announcement is specifically for revisions to an active NCI P01 award. It is not intended for new, stand-alone P01 proposals.
What is the main goal of this revision opportunity?
The main goal is to accelerate cancer research progress by integrating a novel technical approach or instrument that was developed with support from NCI's Innovative Molecular Analysis Technologies (IMAT) program into an ongoing NCI P01 program project, where it can be tested, validated, and used to address important cancer research questions.
What kind of change is NCI looking for in a revision application?
NCI is looking for a substantial, well-justified change to the funded P01 that adds a specific new capability: the integration of an IMAT-supported emerging technology. The revision is expected to be more than an incremental upgrade and should meaningfully change what the parent project can measure, analyze, or discover.
What is the role of IMAT in this funding announcement?
This FOA is positioned as a component of the IMAT program. The revision mechanism is meant to move IMAT-supported technologies from development toward real-world research use by placing them into an established cancer research program project and generating evidence of their value.
What does "independent validation" mean in this context?
The FOA strongly emphasizes independent validation. In practice, the supported revision work should help demonstrate that the IMAT-developed tool or method is reliable and useful in a rigorous cancer research setting, helping show that it is ready for broader adoption by the relevant cancer research community.
How should the proposed technology integration relate to the parent P01?
Applicants are expected to provide a clear rationale explaining why the chosen IMAT-supported technology is a strong match for the scientific aims of the parent P01, how it will be implemented, what validation steps will be used, and how the revision will increase the impact, speed, or scope of the original program project.
What outcomes is NCI trying to achieve through these revisions?
Based on the announcement description, NCI aims to (1) expand the parent P01's original research questions and/or (2) accelerate the pace and impact of the parent study, while also generating validation evidence that supports broader confidence and adoption of IMAT-developed technologies.
Are clinical trials required?
No. The title indicates "Clinical Trial Optional," meaning the revision may include clinical trial-related components if appropriate, but clinical trials are not required to be responsive.
What is the funding mechanism type?
The funding instrument type is a grant, and the announcement explicitly focuses on revision applications to existing awards.
What is the maximum award amount listed for this opportunity?
The award ceiling listed in the source data is $150,000. This suggests a targeted add-on budget intended to support the technology integration and associated validation work, rather than a major expansion of the overall P01.
What is the CFDA number for this opportunity?
The CFDA number listed is 93.394.
What category is this opportunity listed under?
It is described as a discretionary grant opportunity under NIH and categorized under Education and Health.
Who is eligible to apply?
Eligibility is broad by institution type, but the key constraint is programmatic: the applicant must be submitting a revision to an active, currently funded NCI P01 Program Project Grant.
What types of organizations are listed as eligible applicants?
Eligible applicant organizations listed include public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); for-profit organizations (other than small businesses); small businesses; state, county, city/township, and special district governments; tribal governments and tribal organizations; and additional entities such as eligible federal agencies, regional organizations, U.S. territories or possessions, and non-domestic (non-U.S.) entities (foreign organizations).
Are minority-serving institutions specifically included in the eligibility list?
Yes. The announcement highlights eligibility for Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Can faith-based or community-based organizations apply?
Yes. Faith-based or community-based organizations are explicitly included in the eligible groups listed, provided they meet the overarching requirement of revising an active NCI P01 award.
Can non-U.S. (foreign) organizations apply?
Yes. The eligibility list includes non-domestic (non-U.S.) entities (foreign organizations), assuming they can legitimately hold the award and are tied to an eligible, currently funded NCI P01.
What is the key requirement that determines whether an application is responsive?
The central responsiveness requirement described is that the application must be a revision to an active NCI P01 and must add an IMAT-supported novel technical approach or instrument in a way that materially expands or accelerates the parent project and includes meaningful validation.
What dates are associated with this funding announcement?
The creation date shown is 2022-01-03, and the original closing date shown is 2022-09-22.
Why does the FOA emphasize speeding up research rather than starting new projects?
The opportunity is structured to leverage existing P01 teams and infrastructure so an emerging, NCI-backed technology can be inserted into a well-organized program project and rapidly tested and validated, rather than waiting for a new, standalone project cycle.
What should applicants expect reviewers to focus on?
Based on the announcement description, reviewers are expected to look for a clear rationale for the technology choice, a credible implementation plan, well-defined validation steps, and a convincing explanation of how the revision increases the parent P01's impact, speed, or scientific scope.
What is the practical "bridge" this FOA is trying to create?
It is described as a bridge between technology development and real-world research use, encouraging investigators to take an emerging IMAT technology and prove its value through rigorous use and validation within an active cancer research program project.
Browse more opportunities from the same category: Education, Health
Next opportunity: Office of Postsecondary Education (OPE): American Rescue Plan (SSARP) Program, Assistance Listing Number (ALN) 84.425T
Previous opportunity: FY2021 Historic Preservation Fund - Underrepresented Community Grants
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 22 008
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 22 008) also looked into and applied for these:
| Funding Opportunity |
|---|
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional) Apply for RFA CA 22 007 Funding Number: RFA CA 22 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional) Apply for RFA CA 22 010 Funding Number: RFA CA 22 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) Apply for RFA CA 22 006 Funding Number: RFA CA 22 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) Apply for RFA CA 22 005 Funding Number: RFA CA 22 005 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| HEAL Initiative: HEAL Data2Action (HD2A) Data Infrastructure Support Center (U24 Clinical Trial Optional) Apply for RFA DA 22 052 Funding Number: RFA DA 22 052 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,000,000 |
| HEAL Initiative: HEAL Data2Action Research Adoption Support Center (U2C Clinical Trial Optional) Apply for RFA DA 22 050 Funding Number: RFA DA 22 050 Agency: National Institutes of Health Category: Education, Health Funding Amount: $2,000,000 |
| Advancing communication strategies to support future HIV vaccine use (R21 Clinical Trial Optional) Apply for RFA MH 22 171 Funding Number: RFA MH 22 171 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) Apply for RFA CA 22 009 Funding Number: RFA CA 22 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers (U54 Clinical Trial Optional) Apply for RFA CA 22 011 Funding Number: RFA CA 22 011 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed) Apply for PAR 22 057 Funding Number: PAR 22 057 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional) Apply for RFA DA 22 037 Funding Number: RFA DA 22 037 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Health Care Models for Persons with Multiple Chronic Conditions from Populations that Experience Health Disparities: Advancing Health Care towards Health Equity (R01 - Clinical Trials Optional) Apply for PAR 22 092 Funding Number: PAR 22 092 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional) Apply for RFA DA 22 038 Funding Number: RFA DA 22 038 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) Apply for PAR 22 091 Funding Number: PAR 22 091 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed) Apply for PAR 22 090 Funding Number: PAR 22 090 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed) Apply for PAR 22 084 Funding Number: PAR 22 084 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed) Apply for RFA TR 22 011 Funding Number: RFA TR 22 011 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Stimulating Access to Research in Residency (StARR) (R38) Apply for RFA HL 23 006 Funding Number: RFA HL 23 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed) Apply for PAR 22 083 Funding Number: PAR 22 083 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) Apply for PAR 22 099 Funding Number: PAR 22 099 Agency: National Institutes of Health Category: Education, Health Funding Amount: $40,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 22 008", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.